about
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver diseaseNonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients.Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes.The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients.Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis.Response to do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients.Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis.Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis.Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit.Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitusA Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis.A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical studyAdverse drug reactions as a reason for admission to an internal medicine ward in ArgentinaRelationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitisUse of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitusChange in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitisPerformance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 DiabetesEffect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trialRole of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled TrialUse of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 DiabetesLetter to the Editor: "Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content"
P50
Q30235619-3B2E5B8A-9FC3-41F2-BCF6-D45C171CFFDCQ35958498-C1042A77-B211-4EF9-B222-F9A274F951BAQ39002475-0E33A197-A1DC-4239-9CAD-D3ED99623F60Q39041789-0EBC0493-6044-4B37-848D-0D4EFFC98526Q40422340-CA65129F-86F4-4C87-9BE4-2A60B29969A8Q40747515-6AFA471D-056B-4CE2-AB2D-1938560B1185Q40984614-B79967FE-8D3B-4E39-90A9-0935F499965AQ43786135-5BEA9B89-AEDF-4A0B-9F66-9262F125959EQ46124754-98B3878C-49A1-48B7-85AF-B3BECF8BEE8EQ46548459-BB03DC4A-D9FA-4BD5-9C47-BF42E010D384Q47683156-E5D0342F-D0C9-49ED-A7E8-823CAF33E4F7Q47709713-3CDEE426-94EA-4D2F-AB9A-A4889BDBE206Q47765250-5B2B8F1A-7A6D-46CC-B3A3-C6A123571C51Q47868469-CF5FE586-D34B-410B-9FBC-C4FFEA510164Q47976008-024CE36B-343D-4CFC-9140-FD1F598AC038Q48083304-FF0C699F-A958-4504-87A1-86A579A2A861Q48085253-8AE82995-D46D-40AA-A38D-F56A4718FADBQ48086288-A3DCE472-4E9D-4367-8C91-5E97B2861EF4Q48193707-390EE34F-1836-4E41-A366-0358DE16D273Q48194327-E13621F3-42E4-4E0E-A957-415BCC6D7E13Q48218431-825440B9-26C7-45D3-8C0F-DD533922CF40Q51289305-DF303744-E6BC-4680-AA42-6AFDF2F66D14Q51372025-44EFABB2-66F9-46B1-A8BD-E9EFFA5ED9A6Q53747490-82E01E31-4B0A-4975-8A34-730CA255180BQ57478506-C8AFC8DA-A45F-433E-9323-03BDFBEDE76EQ64912299-87901371-B4DC-4E05-B532-7E342E4FAF5DQ85262243-F770156D-4016-4C2F-A786-03756FBDB78BQ85946822-68BAD780-382E-4BB4-B86D-71071027A63EQ87775354-143DE6F0-C081-47B3-9AE3-EE240F32E988Q88022907-215C7CC9-F3D4-40BA-BBB4-7FE955776409Q90565037-EF8CE075-5D6D-4424-AB40-437315901FD0Q90661279-8F8B83BF-3E5C-438F-BC74-9E4DE74F7AC3Q90731527-8F88845B-D521-4AE6-8D88-27ADD14C69CFQ92091070-4760519D-C86A-4645-8177-3209FDD29E5CQ92916188-CD93310B-11E4-4B36-B80C-845DBFAC4A28Q92934792-2AD0E72D-646D-4A07-B350-8CDC4951330B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Fernando Bril
@ast
Fernando Bril
@en
Fernando Bril
@es
Fernando Bril
@nl
type
label
Fernando Bril
@ast
Fernando Bril
@en
Fernando Bril
@es
Fernando Bril
@nl
prefLabel
Fernando Bril
@ast
Fernando Bril
@en
Fernando Bril
@es
Fernando Bril
@nl
P106
P1153
35791540500
P21
P31
P496
0000-0001-5570-4396